prepared mannosylated lactoferrin NPs containing anti‐cancer shikonin and PD‐L1 suppressor JQ1 as a multi‐target therapy.[258] Lactoferrin and mannose promoted targeting of CT26 cancer cells and M2‐type macrophages via low‐density lipoprotein receptor‐related protein 1 and CD206, respectively, which endowed the NPs with robust antitumor effects in mice bearing CT26 colon carcinoma. Here, MRC1 is linked to cancer.